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ABSTRACT
Sensitive and rapid detection of infection with Toxoplasma gondii in transplanted immunocompromised
patients is crucial for a good prognosis. Two DNA fragments are used currently for detecting T. gondii
infection by PCR, i.e., the B1 gene and a 529-bp repeat element that exists in 200–300 copies ⁄ genome.
This study investigated whether targeting the 529-bp repeat element gives better sensitivity and
accuracy than can be obtained when targeting the B1 gene (35 copies) when concentrations of T. gondii
DNA are low. The results demonstrated that detection of the 529-bp repeat element increased diagnostic
sensitivity and accuracy. Addition of an internal ampliﬁcation control did not affect the PCR
performance and was useful in order to monitor PCR inhibition by non-speciﬁc DNA in the LightCycler
instrument. The real-time PCR was used successfully in a clinical context to monitor parasitaemia in the
blood of a transplant recipient suffering from toxoplasmosis.
Keywords B1 gene, diagnosis, internal ampliﬁcation control, real-time PCR, repeat element, toxoplasmosis
Original submission: 28 February 2005; Revised submission: 17 June 2005; Accepted: 27 July 2005
Clin Microbiol Infect 2006; 12: 131–136
INTRODUCTION
Primary infection in healthy individuals with the
protozoan Toxoplasma gondii is often asympto-
matic or characterised by only general symptoms.
The parasite converts to a latent form after
primary infection, and remains in the body,
where it establishes a symptom-free chronic
infection. Reactivation of chronic infection in
transplant patients receiving immunosuppressive
therapy may cause life-threatening disease, often
diagnosed post mortem [1,2]. Early detection of
toxoplasmosis in these patients is critical to
improving the clinical outcome [3].
A variety of real-time PCR assays and PCR
targets have been developed for the rapid and
sensitive detection of T. gondii [4–6], including the
B1 gene, which occurs in 35 copies in the parasite
genome [7–13]. A further repeat element of
unknown function, which occurs in 200–300 cop-
ies, has recently been described in T. gondii [14].
This element is 529 bp in size, and is a promising
target that may provide better real-time PCR
performance [15,16]. It has been postulated that
use of this fragment as a PCR target would increase
the analytical sensitivity of the technique
compared with that obtained when targeting the
B1 gene [17,18]. Accordingly, the primary aim of
the present study was to investigate the sensitivity
and accuracy of an assay targeting the 529-bp
element when analysing samples that contained
ten or fewer T. gondii genome equivalents. The
results obtained were compared with those
obtained when targeting the B1 gene.
A secondary aim of the study was to investigate
whether negative results were caused by PCR
inhibition, e.g., in samples where amounts of non-
speciﬁc DNA are high. PCR inhibition can be
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detected by use of an internal ampliﬁcation
control (IAC) [19–21]. ‘Non-competitive’ IACs
(nIACs) are ampliﬁed by an independent set of
primers, while ‘competitive’ IACs (cIACs) are
co-ampliﬁed by the diagnostic primers. Using
cIACs may give more speciﬁc results than using
nIACs, as cIACs depend directly on the function
of the diagnostic primers.
When performing diagnostic PCRs that include
an IAC, there may be undesirable competition
between the efﬁciency with which the target
(T. gondii) DNA is ampliﬁed and the efﬁciency
with which the IAC is ampliﬁed. If the ampliﬁ-
cation efﬁciency of T. gondii DNA is decreased,
there may be a reduction in detection sensitivity
[22]. The present study investigated whether a
cIAC can be used in a real-time PCR assay
targeting the 529-bp repeat element without
impairing the diagnostic performance of the
PCR. The parasitic burden determined by real-
time PCR has been correlated previously with
clinical symptoms and used to inﬂuence the
choice of treatment [8,23,24]. The real-time PCR
assay targeting the 529-bp repeat element was
assessed further by monitoring parasitaemia in
the blood of a transplant recipient suffering from
reactivated toxoplasmosis.
MATERIALS AND METHODS
DNA extraction
Blood samples were collected in Vacutainer tubes containing
EDTA (Becton Dickinson, Franklin Lakes, NJ, USA); DNA
was also extracted from three genotypes of T. gondii (RH,
NED and Prugniaud). DNA was extracted using a Magna-
Pure LC extraction robot (Roche Diagnostics, Mannheim,
Germany) [25]. The concentration and quality of the DNA
extracted were determined using a ND-1000 Spectrophotom-
eter (Nanodrop Technologies, Wilmington, DE, USA). Each
T. gondii genome was considered to be equivalent to 80 fg
DNA [17].
Real-time PCR SYBR green assay targeting the 529-bp repeat
element and the B1 gene
Two similar real-time PCR assays for T. gondii were designed
using Beacon Designer v.2.1 (Premier Biosoft International,
Palo Alto, CA, USA), one targeting the 529-bp repeat element
and the other targeting the B1 gene, based on the aligned
sequences of the 529-bp repeat element (accession numbers
AF146527 and AF487550) and the B1 gene [26]. Primers
targeting the 529-bp element were 5¢-CACAGAAGGG
ACAGAAGT and 5¢-TCGCCTTCATCTACAGTC, which
ampliﬁed a 94-bp internal fragment. Primers for the B1 gene
were 5¢-CGTCCGTCGTAATATCAG and 5¢-GACTTCATGG
GACGATATG, which ampliﬁed a 98-bp internal fragment.
The assay targeting the 529-bp repeat element was designated
‘toxo-529’, and the assay targeting the B1 gene was designated
‘toxo-B1’.
LightCycler FastStart DNA Master SYBR green mix (Roche
Diagnostics) was mixed with different concentrations of T.
gondii DNA, 250 nM primers and 4 mM MgCl2. The toxo-529
and toxo-B1 assayswere run simultaneously in a LightCycler 2.0
instrument (Roche Diagnostics), with a 10-min hot-start at 95C,
followedby45 cycles of 95Cfor 5 s, 60Cfor 5 s and72Cfor 5 s.
The cycle number at which the ﬂuorescence signal ﬁrst exceeds
the level of background ﬂuorescence is termed the ‘crossing
point (CP) value’, and was determined automatically by the
LightCycler software for each run. The programme concluded
with melting curve analysis. No-template controls (NTC) and
no-ampliﬁcation controls (NAC) were included in this assay. A
standard curve for calculating ampliﬁcation efﬁciency and error
was constructed by diluting T. gondii DNA serially and analy-
sing ﬁve concentrations (8 ng, 800 pg, 80 pg, 8 pg and 800
fg ⁄ sample) in triplicate.
The sensitivity and accuracy of the toxo-529 and toxo-B1
assays with low sample concentrations of T. gondii DNA were
also analysed. Ten different extracts of T. gondii DNA were
diluted serially and analysed in triplicate, with 800 fg, 80 fg, 8
fg and 0.8 fg, respectively, present in the samples. Melting
curve analysis was used to verify that the correct product had
been ampliﬁed in positive samples.
Design of cIAC
A 130-base oligonucleotide was constructed that contained the
toxo-529 sense and antisense primer-binding sites and a probe-
binding site that differed from that of the 529-bp repeat element.
This oligonucleotide (0.1 pmol) was ampliﬁed by conventional
PCR (GeneAmp PCR System 9700; Applied Biosystems, Stock-
holm, Sweden) using 400 nM sense and antisense primers,
1.5 mM MgCl2, 1 · PCR Gold buffer, 200 lM each dNTP
(Sigma-Aldrich, Stockholm, Sweden) and 1.25 U of AmpliTaq
Gold enzyme (Applied Biosystems) in a 50-lL reaction with 30
cycles of 94C for 30 s, 55C for 30 s and 72C for 30 s, followed
by a ﬁnal extension for 5 min at 72C. The PCR product was
puriﬁed (QIAquick PCR Puriﬁcation Kit; Qiagen, Valencia, CA,
USA) and then digested, together with pcDNA3 plasmid DNA
(Invitrogen, Paisley, UK) with EcoR1 and Xho1 (New England
Biolabs, Beverly, MA, USA) for 6 h at 37C. The digestion
products were separated by electrophoresis on agarose gels and
puriﬁed (QIAquick Gel Extraction Kit; Qiagen). The plasmid
and the insert were mixed at a ratio of 1: 4 and ligated overnight
at 4C with T4 ligase (New England Biolabs). Ligated plasmid
was transformed into XL1-blue bacteria (Stratagene, La Jolla,
CA, USA) and positive clones were selected as described by the
manufacturer. The resulting cIACplasmidwaspuriﬁed (Qiagen
Spin Miniprep Kit; Qiagen) and sequenced (ABI Prism 310;
Applied Biosystems) in order to verify that the oligonucleotide
had been inserted.
Real-time PCR TaqMan with cIAC or nIAC targeting the
529-bp repeat element
TaqMan probes were designed (Beacon Designer v.2.1) and
used together with the toxo-529 primers in a TaqMan assay
targeting the 529-bp repeat element. This TaqMan assay was
used to investigate the ampliﬁcation efﬁciency with two
different types of IAC, i.e., cIAC (see above) and nIAC. The
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nIAC was based on ampliﬁcation of Arabidopsis thaliana DNA
using 250 nM of A. thaliana primers 5¢-ATAACAGG-
CAATCCATATGA and 5¢-ATGAAGTCTATGGAGAAACC.
The resulting 148-bp fragment was detected using 125 nM of
the cIAC TaqMan probe (see below). The concentration of A.
thaliana DNA was chosen such that the CP was c. 35. The
TaqMan assay including the cIAC was designated ‘toxo-529-
cIAC’, and the TaqMan assay including the nIAC was
designated ‘toxo-529-nIAC’.
T. gondii DNA was detected in toxo-529-cIAC and toxo-529-
nIAC using 500 nM sense and antisense primers from toxo-
529, and 125 nM of TaqMan probe 5¢-FAM-CTCTCCTCCAA-
GACGGCTGG-BHQ1 speciﬁc for the 529-bp repeat element.
The toxo-529-cIAC and toxo-529-nIAC assays were performed
in a LightCycler 2.0 instrument; all samples included 1 lg of
human blood cell DNA. A 10-min hot-start at 95C was
followed by 45 cycles of 95C for 5 s, 60C for 5 s and 65C for
10 s. CPs were determined automatically. NTC and NAC
controls were included.
The toxo-529-cIAC assay was performed by amplifying and
detecting a 114-bp fragment of the cIACplasmid using the toxo-
529 primers and 125 nM of the cIAC TaqMan probe 5¢-HEX-
TAAGCCATCACAAGCATCTCAGC-BHQ1. The amount of
cIAC plasmid in a sample was chosen such that the CP was
c. 35.
In-vitro performance of the toxo-529-cIAC and toxo-529-
nIAC assays
The ampliﬁcation efﬁciency and the error obtained using cIAC
or nIAC were compared by adding LightCycler FastStart DNA
Master Hybridization Probes mix (Roche Diagnostics) and
1 lg human blood cell DNA to each sample. T. gondii DNA
was diluted serially in ten-fold steps. Samples containing 8 ng,
800 pg, 80 pg, 8 pg, 800 fg or 80 fg of T. gondii DNA were
analysed in triplicate using a LightCycler 2.0 instrument; the
ampliﬁcation efﬁciency and the error were calculated using
LightCycler v.4.0 software.
The possibility that TaqMan probes, cIAC or non-speciﬁc
DNA inﬂuenced the sensitivity and accuracy of the real-time
PCR was investigated by analysing one T. gondii genome
equivalent (80 fg DNA) in a sample by both toxo-529-cIAC and
toxo-529. Ten different T. gondii DNA extracts were analysed
in triplicate. Human blood cell DNA (1 lg) was included in
each sample for toxo-529-cIAC; no human blood cell DNA was
included in the samples for toxo-529.
Clinical utility of the toxo-529-cIAC assay
The speciﬁcity of the toxo-529-cIAC assay was tested using
three different genotypes of T. gondii, namely RH, NED and
Prugniaud. The assay was also tested with 50 blood samples
from immunocompromised patients who had previously
tested negative for T. gondii with a different PCR method
[27]. The clinical utility of toxo-529-cIAC was demonstrated by
monitoring one case of toxoplasmosis over time. Blood
samples taken on three consecutive days from a transplant
recipient suffering from toxoplasmosis were analysed. The
performance of toxo-529-cIAC in relation to the amount of
non-speciﬁc DNA present in a sample was examined by
analysing triplicate samples containing one T. gondii genome
equivalent in the presence of 1, 1.5, 2 or 4 lg of human blood
cell DNA.
RESULTS
In-vitro performance of the toxo-529 and toxo-
B1 assays
The theoretical optimum ampliﬁcation efﬁciency
is 2 [17]. The ampliﬁcation efﬁciency for toxo-529
was 1.95 (error 0.036), while that for toxo-B1 was
1.91 (error 0.081); thus the performance of both
assays was considered to be satisfactory. The
detection limit was deﬁned as the amount of
T. gondii DNA for which all 30 samples analysed
yielded a positive result. Table 1 shows that the
detection limit for toxo-529 was one genome
equivalent (80 fg DNA) per sample, while that
for toxo-B1 was ten parasitic genomes (800 fg
DNA) per sample. Thus, toxo-529 was more
sensitive than toxo-B1. Furthermore, the coefﬁ-
cient of variation (CV) was lower for toxo-529
than for toxo-B1; thus toxo-529 was more accurate
than toxo-B1.
In-vitro performance of the toxo-529-cIAC and
toxo-529-nIAC assays
The ampliﬁcation efﬁciency for toxo-529-cIAC
was 1.90 (error 0.041), while that for toxo-529-
nIAC was 1.90 (error 0.003); thus, the use of nIAC
and cIAC resulted in the same efﬁciency of
ampliﬁcation of the repeat element. This indicated
that the 529-bp repeat element (200–300 copies)
can be used in conjunction with cIAC or nIAC
without affecting the ampliﬁcation efﬁciency.
cIAC was used in subsequent experiments as this
system was considered to be more speciﬁc than
nIAC and eliminates the need for additional
primers.
All 30 samples containing 80 fg T. gondii DNA
were positive when analysed with toxo-529-cIAC
and toxo-529. The mean CP for toxo-529-cIAC
was 33.6 (CV 2.2%), compared with 32.3 (CV
Table 1. Comparison of sensitivity and accuracy of Light-
Cycler PCR SYBR green assays targeting the 529-bp repeat
element (toxo-529) and the B1 gene (toxo-B1) of Toxoplasma
gondii
DNA
(fg)
Toxo-529 Toxo-B1
Positive
Mean
CP 95% CI
CV
(%) Positive
Mean
CP
95%
CI
CV
(%)
800 30 28.9 28.7–29.1 1.7 30 32.1 31.3–32.8 3.5
80 30 32.3 31.8–32.7 2.8 19 36.1 34.8–37.3 4.0
8 10 36.1 35.5–36.7 2.6 6 40.0 39.2–40.7 2.2
0.8 7 38.0 37.0–39.0 3.5 0 – – –
CP, mean crossing point; CV, coefﬁcient of variation.
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2.8%) for toxo-529. Thus the sensitivity and
accuracy were not affected by the presence of
probes, cIAC and 1 lg of human blood cell DNA
when analysing one T. gondii genome equivalent
(80 fg DNA) in a sample.
Clinical utility of the toxo-529-cIAC assay
DNA from the RH, NED and Prugniaud strains of
T. gondii was ampliﬁed successfully by toxo-529-
cIAC. All 50 patient samples were negative,
which is in accordance with the results obtained
by a different PCR method [27]. The cIAC was
ampliﬁed successfully in all negative patient
samples, with a mean CP of 35.4 (CV 2.2%),
thereby demonstrating that the PCR was not
inhibited.
Fig. 1 shows the results obtained when toxo-
529-cIAC was used for three consecutive days to
monitor parasitaemia in blood from a transplant
recipient suffering from reactivated toxoplasmo-
sis. Treatment for toxoplasmosis was initiated at
day 1. The level of T. gondii DNA in blood
increased despite treatment, and the patient died
on day 3. Each analysis required only 2 h (inclu-
ding DNA extraction).
Experiments with one T. gondii genome equiv-
alent (80 fg DNA) in a sample showed that the CP
increased when >1 lg of non-speciﬁc DNA was
present, as did the CP of cIAC (Fig. 2). Thus, cIAC
ampliﬁcation was inhibited in the same manner
as ampliﬁcation of T. gondii DNA, and the cIAC
can therefore be used to detect inhibition of
ampliﬁcation in a ‘negative’ sample.
DISCUSSION
Previous studies have shown that PCR-based
detection of multicopy targets is more sensitive
for diagnosing toxoplasmosis than is detection of
single-copy targets [6,17], while other studies
have yielded contrasting results [4,5]; indeed,
assays have even given different results in differ-
ent circumstances [28–30]. The concentration of T.
gondii DNA may be low during the initial reac-
tivation of toxoplasmosis. A sensitive and accu-
rate method is required in order to facilitate early
diagnosis of toxoplasmosis in immunocompro-
mised transplant recipients. The present study
demonstrated that PCR targeting the 529-bp
element (which occurs in more copies than the
B1 gene) is more sensitive and accurate when
analysing low levels of T. gondii DNA in a sample.
Internal control systems are important in order
to detect whether a PCR has been inhibited, but
these controls may, in some cases, reduce the
sensitivity and accuracy of diagnostic PCR by
competing for the reagents [22]. The present study
found that the sensitivity and accuracy of toxo-
529-cIAC and toxo-529 for detecting the equival-
ent of one T. gondii genome in a sample was
not affected when probes, cIAC or 1 lg of
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Fig. 1. Use of real-time PCR target-
ing the 529-bp repeat element of
Toxoplasma gondii to monitor
parasitaemia in blood for three
consecutive days in an immunocom-
promised transplanted patient.
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Fig. 2. Inﬂuence of different amounts of human blood cell
DNA on real-time PCR targeting a 529-bp repeat element
of Toxoplasma gondii, with the inclusion of a competitive
internal ampliﬁction control (cIAC). One T. gondii genome
equivalent (80 fg) was mixed with 1, 1.5, 2 or 4 lg human
blood cell DNA, and tested in triplicate. Toxo-529 shows
the crossing points (CPs) for T. gondii DNA ampliﬁcation,
and cIAC shows those for cIAC. The CP increases with
increased amounts of non-speciﬁc DNA, showing that the
PCR is inhibited. cIAC is sensitive to inhibition and can be
used to detect inhibition in ‘negative’ samples. When
samples containing 4 lg of non-speciﬁc DNA are analysed,
inhibition of the PCR is so severe that cIAC is not
ampliﬁed.
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non-speciﬁc DNA were added. Hence, cIAC can
be used with a 200–300-fold repetitive PCR target
without loss of diagnostic performance.
The cIAC was considered to be a more speciﬁc
control system than the nIAC, as the cIAC
depends directly on the diagnostic primers and
does not require any additional primers. How-
ever, ampliﬁcation of the cIAC competes with that
of the T. gondii DNA. The results obtained suggest
that this can be circumvented when the diagnostic
target occurs in 200–300 copies by careful balan-
cing of the cIAC to a minimal, but reproducibly
detectable, concentration. The cIAC can also be
used to monitor inhibition more carefully when
its concentration is at a minimum than when it is
present at higher concentrations. High amounts of
non-speciﬁc DNA in a sample inhibited the
LightCycler PCR when targeting the B1 gene,
which occurs in 35 copies [31]. This also appeared
to be the case for the 529-bp element, which
occurs in many more copies. Spectrophotometric
analysis can be used to avoid overload of sample
DNA in the PCR.
Real-time PCR can be used to diagnose toxo-
plasmosis in the clinical context, to monitor the
efﬁcacy of treatment, and to correlate parasitae-
mia with clinical symptoms [9]. Treatment for
reactivated toxoplasmosis in the case mentioned
above was ineffective, possibly because it was
delayed in its initiation. This highlights the
importance of early diagnosis of toxoplasmosis.
However, PCR ampliﬁes DNA from both live and
dead parasites. The number of parasites in blood
may therefore be overestimated, depending on
the stability of T. gondii DNA. The present study
demonstrated that low concentrations of T. gondii
DNA could be detected more sensitively and
accurately by real-time PCR using the 529-bp
repeat element of T. gondii than when using the B1
gene. The 529-bp element is suitable for use with a
cIAC, which detects efﬁciently whether the PCR
has been inhibited. The procedures investigated
are rapid and sensitive, and suitable for routine
use. Early diagnosis of toxoplasmosis in immuno-
compromised transplanted patients should signi-
ﬁcantly improve the rate of successful treatment.
The 529-bp repeat element may become the
preferred target when real-time PCR, including
IAC, is used to diagnose toxoplasmosis. However,
further work is required to ensure that this PCR
target is conserved among different strains of
T. gondii.
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